Beijing Hotgen Biotech Co., Ltd. (Hotgen Biotech, stock code: 688068) was founded in June 2005 as a high-tech enterprise focusing on the research & development, manufacture, and sales of medical and public safety clinical products of in vitro diagnostics (IVD) in the field of biomedicine. Hotgen Biotech was listed on the China Sci-Tech innovation board (STAR Market) in September 2019.
After several years of Research& development, Hotgen Biotech has developed 8 major technology platforms, such as In Vitro diagnostic reagent bioactive raw material development platform, glycoprotein capture technical platform, magnetic particles chemiluminescence, up-converting Phosphor, and colloidal gold-based immunoassay. These technology platforms form a closed-loop system for in vitro diagnostic R&D and production.
Hotgen Biotech has established a complete full level immunodiagnostic platform, from high-precision up-converting phosphor POCT (UPT series), low- to high-throughput single-cartridge chemiluminescence platforms (MQ60 series), and then to large-scale full-automatic chemiluminescence platform (C2000), which facilitates the application of the immunodiagnostic platform in various diagnostic scenarios. Hotgen Btiotech’s products are widely used in the clinical and public safety fields. The specific users include not only hospitals at all levels, township health centers, third-party testing centers, and medical institutions, but also disaster response units, customs, food and medicine inspection, food and feed enterprises, and other public safety fields.
"Products’ quality determines the company's principle,
customers determine the company's accomplishments,
talents determine the company's growth,
innovation determines the company's future".
Developing Biotechnology and benefiting Human Health
Promote technological entrepreneurship
Nurture industrial development